Species differences in metabolism of panomifene, an analogue of tamoxifen

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1370-1378

  Monostory, Katalin ^a   Jemnitz, Katalin ^b   Vereczkey, Laszlo ^b   Czira, Gabor ^b  

^a CTRL RES INSTITUTE FOR CHEMISTRY   (Hungary)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PANOMIFENE; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTRANSFORMATION; BREAST CANCER; DRUG ACTIVATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RODENT; SPECIES DIFFERENTIATION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; BIOTRANSFORMATION; DOGS; HUMANS; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; RATS; SPECIES SPECIFICITY; TAMOXIFEN;

EID: 0031463868     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. C. S. Murphy, C. J. Parker, R. McCague, and V. C. Jordan: Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol. Pharmacol. 39, 421-428 (1991).
2. S. D. Lyman and V. C. Jordan: Metabolism of nonsteroidal antiestrogens. In "Estrogen/Antiestrogen Action and Breast Cancer Therapy" (V. C. Jordan, ed.), pp. 191-219. The University of Wisconsin Press, Madison, WI, 1986.
3. C. K. Lim, Z-X. Yuan, J. H. Lamb, I. N. H. White, F. De Matteis, and L. L. Smith: A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15, 589-593 (1994).
4. C. Mani, H. V. Gelboin, S. S. Park, R. Pearce, A. Parkinson, and D. Kupfer: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645-656 (1993).
5. C. Mani, R. Pearce, A. Parkinson, and D. Kupfer: Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15, 2715-2720 (1994).
6. H. K. Crewe, S. W. Ellis, M. S. Lennard, and G. T. Tucker: Variable contribution of cytochrome P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171-178 (1997).
7. N. M. Meltzer, P. Stang, L. A. Sternson, and A. E. Wade: Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem. Pharmacol. 33, 115-123 (1984).
8. I. N. H. White, A. Davies, L. L. Smith, S. Dawson, and F. Matteis: Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol. 45, 21-30 (1993).
9. J. Dauplat, G. LeBouedec, and J. L. Achard: Endometrial adenocarcinoma in 2 patients taking tamoxifen. Presse Med. 19, 380-381 (1990).
10. T. Fornander: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 4, 117-119 (1989).
11. V. C. Jordan: Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu. Rev. Pharmacol. Toxicol. 35, 195-211 (1995).
12. J. M. J. Diver, I. M. Jackson, and J. D. Fitzgerald: Tamoxifen and non-malignant indications. Lancet 1, 733 (1986).
13. I. S. Fentiman and T. J. Powles: Tamoxifen and benign breast problems. Lancet 2, 1070-1072 (1987).
14. K. C. Fendl and S. J. Zimniski: Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res. 52, 235-237 (1992).
15. B. Moorthy, P. Sriram, D. N. Pathak, W. J. Bodell, and K. Raderath: Tamoxifen metabolic activation: comparison of DNA adducts formed by microsomal and chemical activation of taraoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 56, 53-57 (1996).
16. T. A. van der Hoeven and M. J. Coon: Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249, 6302-6310 (1974).
17. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
18. C. Mani, E. Hodgson, and D. Kupfer: Metabolism of the antimammary cancer antiestrogenic agent tamoxifen II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos. 21, 657-661 (1993).
19. P. C. Ruenitz, J. R. Bagley, and C. W. Pape: Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen. Drug Metab. Dispos. 12, 478-483 (1984).
20. C. Mani and D. Kupfer: Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res. 51, 6052-6058 (1991).